53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003749-39-IT (EUCTR)	15/12/2021	15/10/2021	A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A.	A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. - NGF0221	Severe Sjogren’s dry eye disease MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Oxervate Product Name: OXERVATE Product Code: [Recombinant Human Nerve Growth Factor (rhNGF)] INN or Proposed INN: Cenegermin Other descriptive name: Recombinant form of human nerve growth factor produced in Escherichia Coli.	DOMPé FARMACEUTICI S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	United States;Italy
2	ChiCTR-IPR-15005990	2015-03-23	2015-02-10	Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Sjogren's syndrome	Treatment group:glucocorticoid+CsA;Control group:glucocorticoid+placebo;	Peking University People's Hospital	NULL	Pending	18	75	Both	Treatment group:120;Control group:120;		China
3	NCT02370550 (ClinicalTrials.gov)	March 2015	18/2/2015	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Sjogren's Syndrome	Drug: Cyclosporin A;Drug: Prednisone;Drug: Placebo;Drug: Calcium carbonate D	Peking University People's Hospital	NULL	Recruiting	18 Years	75 Years	All	240	Phase 4	China
4	NCT01693393 (ClinicalTrials.gov)	March 2010	14/9/2012	Low Dose Cyclosporin A in Primary Sjögren Syndrome	A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome	Sjögren´s Syndrome	Drug: Cyclosporine A	Charite University, Berlin, Germany	NULL	Completed	18 Years	75 Years	Both	30	Phase 2	Germany
5	EUCTR2009-013976-38-DE (EUCTR)		07/12/2009	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Primary Sjögren's Syndrome MedDRA version: 12.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome	Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN	Charité Berlin, Department of rheumatology	Charité Berlin, department of rheumatology;Charité Berlin, department of rheumatology	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany